Breaking Finance News

JMP Securities reported on Clearside Biomedical (US:CLSD), raising its target price to $21.00 earlier today

JMP Securities increased the stock price target of Clearside Biomedical (US:CLSD) to $21.00 reporting a potential upside of 1.79%.

Boasting a price of $7.54, Clearside Biomedical (US:CLSD) traded 2.47% higher on the day. With the last close down -6.05% from the two hundred day average, compared with the S&P 500 which has increased 0.02% over the same time. The company has recorded a 50-day moving average of $7.79 and a 200-day moving average of $7.96. 79,558 shares of CLSD traded hands, down from an average trading volume of 132,727

Recent Performance Chart

Clearside Biomedical (US:CLSD)

Clearside Biomedical has 52 week low of $5.44 and a 52 week high of $25.08 and has a market cap of $0.

Also covering Clearside Biomedical's target, a total of 3 analysts have released a research note on CLSD. The one year target is $19.00 with 0 firms rating the stock a strong buy, 0 equity analysts rating the company a buy, zero equity analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the company a sell.

More About Clearside Biomedical (US:CLSD)

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *